Platelet cytosolic free calcium in essential hypertension: responses to vasopressin

A F Dominiczak1, J J Morton, G Murray

  • 1MRC Blood Pressure Unit, Western Infirmary, Glasgow, Scotland, U.K.

Insights

Essential hypertension patients show normal resting platelet calcium but a blunted response to arginine vasopressin when extracellular calcium is present. Drug treatment for hypertension correlated with changes in platelet calcium levels.

Area of Science:

  • Cardiovascular Physiology
  • Cellular Biology

Background:

  • Essential hypertension is a complex cardiovascular condition.
  • Platelet calcium homeostasis plays a role in vascular function.

Purpose of the Study:

  • To investigate platelet free calcium concentrations in essential hypertension.
  • To assess the effect of arginine vasopressin on platelet calcium in hypertensive patients.
  • To examine the impact of antihypertensive drugs on platelet calcium.

Main Methods:

  • Measurement of platelet free calcium using the fluorescent probe quin2.
  • Stimulation of platelets with arginine vasopressin in the presence and absence of extracellular calcium.
  • Correlation analysis of blood pressure changes with platelet calcium alterations after drug treatment.

Main Results:

  • No significant difference in resting cytosolic free calcium between hypertensive and normotensive groups.
  • Arginine vasopressin induced a significantly lower increase in platelet free calcium in hypertensive patients compared to controls when extracellular calcium was present.
  • Absence of extracellular calcium abolished the difference in response between groups.
  • Reductions in systolic blood pressure after verapamil or atenolol treatment correlated with changes in platelet cytosolic free calcium.

Conclusions:

  • Essential hypertension is not associated with altered resting platelet calcium levels.
  • Hypertensive patients exhibit impaired platelet calcium mobilization in response to arginine vasopressin, particularly when extracellular calcium is available.
  • Antihypertensive therapy may influence platelet calcium dynamics, suggesting a potential link between blood pressure control and cellular calcium handling.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...